Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice.

Serial CTRS, an AI-powered tool, has been granted FDA breakthrough device designation for classifying patients with NSCLC. The FDA has granted breakthrough device designation to Serial CTRS, a ...

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer. The selective oral CDK4/6 ...

C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE ...

EP: 4.Handling Dose Modifications and Treatment Interruptions Due to AEs With Bispecifics ...

Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC ...